LaunchCyte

Brett Richey, the founder and managing partner, drives investment and incubation decisions. He is supported by a small in-house team, and the firm installs dedicated executive talent at each portfolio company post-formation. Richey's operating authority is embedded in the firm's structure as a holding company, where subsidiary-level decisions are overseen through board seats and operational management rather than a traditional investment committee.

LaunchCyte is structured as a private holding company, not a blind-pool fund. It creates wholly owned subsidiaries for each technology it licenses from partner universities, capitalizing them individually and providing shared services from the parent entity. This permanent-capital architecture avoids the fixed exit timelines that govern traditional venture capital funds.

LaunchCyte maintains deep licensing and sourcing relationships with both institutions, acting as a commercial translation layer for faculty and graduate research. The firm identifies technologies ready for company formation, negotiates intellectual property licenses, and builds the operational company around the academic founders — who typically remain at the university while serving as scientific advisors to the new entity.

LaunchCyte capitalizes its subsidiary companies through a combination of its own balance sheet and co-investors brought in on a deal-by-deal basis. The firm has not disclosed whether it maintains a formal LP base, though portfolio company Peptilogics raised capital from external venture investors including Founders Fund, indicating a willingness to syndicate specific positions.

The firm writes initial checks of $250,000 to $500,000 at the company-formation stage, accompanied by in-kind operational infrastructure — finance, legal, HR, and business development support. LaunchCyte typically retains majority ownership through the earliest development phases and does not participate in later-stage rounds beyond its initial creation-stage involvement.